Therapeutic Effect of Anti-inflammatory Tripeptide Cream in Hand-Foot Syndrome/Skin Reaction Related to Anticancer Drugs: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial
Cancer Research and Treatment · 2024
DOI: 10.4143/crt.2024.080 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Cancer Research and Treatment, 2024. Verfasst von Yaewon Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea. Hauptthemen laut MEDLINE: Hand-Foot Syndrome, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Korean Society of Medical Oncology, National Research Foundation of Korea, Ministry of Education, Science, and Technology.
Abstract (Originalsprache)
Purpose
Hand-foot syndrome (HFS) and hand-foot skin reaction (HFSR) are relatively common toxicities that interfere with the quality of life (QoL) of patients with cancer. Anti-inflammatory tripeptide cream (ATPC) is a complex formulation of anti-inflammatory tripeptides, the CD99-agonist Binterin and the Wnt-antagonist Winhibin. The present study aimed to assess the therapeutic effects of ATPC in HFS/HFSR associated with anticancer drugs.Materials and Methods This was a single-center, randomized, double-blind, placebo-controlled trial. Patients who developed grade 1 HFS/HFSR after systemic anticancer treatments were enrolled, and randomly assigned to receive either ATPC or placebo cream (PC) and followed up at 3-week intervals for up to 9 weeks. Primary endpoint was the development of grade ≥ 2 HFS/HFSR.
Results
Between April 2019 and July 2022, 60 patients (31 in the ATPC and 29 in the PC group) completed the study. The incidence of grade ≥ 2 HFS/HFSR was significantly lower in the ATPC than in the PC group (25.8% vs. 51.7%, p=0.039). The ATPC showed trends towards a better QoL score, assessed by a HFSR and QoL questionnaire at 9 weeks (26.0 vs. 29.9, p=0.574), and a lower frequency of discontinuation, interruption, or dose reduction of anticancer drugs (51.6% vs. 58.6%, p=0.586) than the PC group over 9 weeks, though without statistical significance.
Conclusion
Our results showed that ATPC significantly decreased the development of grade ≥ 2 HFS/HFSR in patients already with HFS/HFSR. Therefore, ATPC may be an effective treatment for HFS/HFSR associated with anticancer drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea.
- Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Korea.
- Department of Anatomy and Cell Biology, Kangwon National University School of Medicine, Chuncheon, Korea.
- SupadElixir Co., Ltd., Chuncheon, Korea.
Förderung
- Korean Society of Medical Oncology
- National Research Foundation of Korea
- Ministry of Education, Science, and Technology
Zitieren
APA
Yang, Y., Hahn, J. H., Kim, M. S., Jo, M., Lee, Y. P., Kim, H., Kim, H. K., Kwon, J., Lee, K. H., & Han, H. S. (2024). Therapeutic Effect of Anti-inflammatory Tripeptide Cream in Hand-Foot Syndrome/Skin Reaction Related to Anticancer Drugs: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial. Cancer Research and Treatment. https://doi.org/10.4143/crt.2024.080
Vancouver
Yang Y, Hahn JH, Kim MS, Jo M, Lee YP, Kim H, et al. Therapeutic Effect of Anti-inflammatory Tripeptide Cream in Hand-Foot Syndrome/Skin Reaction Related to Anticancer Drugs: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial. Cancer Research and Treatment. 2024. doi:10.4143/crt.2024.080
BibTeX
@article{Yang2024,
author = {Yang, Yaewon and Hahn, Jang-Hee and Kim, Min Seo and Jo, Minkwan and Lee, Yong-Pyo and Kim, Hongsik and Kim, Hee Kyung and Kwon, Jihyun and Lee, Ki Hyeong and Han, Hye Sook},
title = {Therapeutic Effect of Anti-inflammatory Tripeptide Cream in Hand-Foot Syndrome/Skin Reaction Related to Anticancer Drugs: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial},
journal = {Cancer Research and Treatment},
year = {2024},
doi = {10.4143/crt.2024.080}
}
EUVIMED